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n response to inﬂammatory stimulation, dendritic cells (DCs)
have a remarkable pattern of differentiation (maturation)
that exhibits speciﬁc mechanisms to control antigen
processing and presentation. One of these mechanisms is
the sorting of polyubiquitinated proteins in large cytosolic
aggregates called dendritic cell aggresome-like induced
structures (DALIS). DALIS formation and maintenance are
tightly linked to protein synthesis. Here, we took advantage
of an antibody recognizing the antibiotic puromycin to
follow the fate of improperly translated proteins, also called
defective ribosomal products (DRiPs). We demonstrate that
I
 
DRiPs are rapidly stored and protected from degradation in
DALIS. In addition, we show that DALIS contain the ubiquitin-
activating enzyme E1, the ubiquitin-conjugating enzyme
E2
 
25K
 
, and the COOH terminus of Hsp70-interacting protein
ubiquitin ligase. The accumulation of these enzymes in
the central area of DALIS deﬁnes speciﬁc functional sites
where initial DRiP incorporation and ubiquitination occur.
Therefore, DCs are able to regulate DRiP degradation in
response to pathogen-associated motifs, a capacity likely
to be important for their immune functions.
 
Introduction
 
Dendritic cells (DCs) are regulators of the immune response,
and control their antigen-processing activities in response
to inflammatory stimuli (e.g., lipopolysaccharide [LPS]; Ban-
chereau and Steinman, 1998). Among antigen-presenting
cells, DCs are the most efficient at initiating antigen-specific
responses, inducing differentiation of both naive CD4
 
 
 
 and
CD8
 
 
 
 T cells (Banchereau and Steinman, 1998). In their
immature state, DCs reside in peripheral tissues where they
detect and capture incoming pathogens. DCs then begin a
maturation process characterized by dramatic phenotypic and
functional changes (Mellman and Steinman, 2001). Previously,
we have shown that upon DC activation, large polyubiquiti-
nated protein aggregates, named dendritic cell aggresome-like
induced structures (DALIS), are formed (Lelouard et al.,
2002). In contrast to classical aggresomes (Kopito, 2000),
DALIS are neither localized in the pericentriolar area nor
caged with vimentin (Heath et al., 2001). Moreover, DALIS
form transiently, being detectable as soon as 4 h after DC acti-
vation and disappearing 24–36 h later (Lelouard et al., 2002).
Interestingly, DALIS formation and maintenance requires
continuous protein synthesis, suggesting that most of the
molecular material incorporated in the aggregates is likely to be
made of ubiquitinated newly synthesized proteins. Importantly,
a large proportion of newly synthesized proteins (up to 30%)
is known to be ubiquitinated and degraded by the proteasome
shortly after synthesis (Wheatley et al., 1980; Schubert et al.,
2000). Most of these substrates, termed defective ribosomal
products (DRiPs), are not functional due to errors in the
process  of protein synthesis, such as misincorporation of
amino acids and premature termination or deletion of residues,
as well as post-translational mistakes occurring during folding,
oligomer assembly, or intracellular triage. Recently, DRiPs
have been proposed to be a major source of self or viral anti-
genic peptides for MHC class I restricted presentation (Reits
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et al., 2000; Schubert et al., 2000; Khan et al., 2001; Yewdell
and Bennink, 2001; Yewdell et al., 2001; Princiotta et al.,
2003). Regulation of DRiP degradation in antigen-presenting
cells could therefore affect the processing of many antigens,
and thereby MHC class I restricted presentation (Schwab et
al., 2003; Yin et al., 2003). Thus, we investigated the contri-
bution of improperly translated proteins to DALIS formation
during DC activation. The antibiotic puromycin was used to
follow DRiPs both biochemically and visually during DC
maturation. Puromycin is mistakenly inserted during protein
synthesis by the ribosome in place of normal amino acids, re-
sulting in truncated nascent polypeptide chains containing the
drug at their COOH termini (Vazquez, 1974). This trunca-
tion creates a pool of aberrantly folded newly synthesized pro-
teins rapidly degraded by the proteasome (Goldberg, 1972;
Etlinger and Goldberg, 1980) and equivalent at least in part
to natural DRiPs. Here, we report that puromycin-labeled
DRiPs are targeted to DALIS 
 
 
 
5 min after their synthesis.
We also show that DALIS serve as specific zones for DRiP
ubiquitination and storage over long periods, their center be-
ing particularly important in DRiP integration and ubiqui-
tination. Therefore, DCs are able to regulate DRiP degrada-
tion through DALIS formation, a capacity likely to be
important for their immune functions.
 
Results
 
Puromycin-labeled proteins are targeted to DALIS
 
DALIS formation and maintenance are abrogated by protein
synthesis inhibitors, whereas drugs promoting abnormal pro-
tein synthesis, such as canavanin or puromycin, act as DALIS
enhancers (Table I; Lelouard et al., 2002). Puromycin is an op-
timal tool to induce improper translation of proteins and estab-
lish the fate of this important population of antigens during
DC activation. After incubation of LPS-treated mouse bone
marrow-derived DCs (Inaba et al., 1992) with limited concen-
trations of puromycin for 30 min, we used a pAb able to detect
puromycin-labeled proteins (Zhang et al., 1997) to perform
immunofluorescence confocal microscopy (Fig. 1 A). Puromy-
cin-labeled proteins were strongly enriched in DALIS, as dem-
onstrated by their colocalization with polyubiquitinated pro-
teins (Ub-proteins) in detergent-extracted DC. The puromycin
found in the aggregates is clearly associated with newly synthe-
sized proteins because puromycin detection in DALIS was
eliminated by a cotreatment with the translation inhibitor cy-
cloheximide (Fig. 1 B, CHX). Additional control experiments
showed that puromycin treatment does not induce DC matu-
ration or DALIS formation, and that puromycin-labeled pro-
teins incorporated into DALIS are resistant to salt extraction
(Fig. 1 B). Immunodetection of puromycin-labeled proteins in
DCs, incubated with different concentrations of antibiotic be-
fore DALIS enrichment (Lelouard et al., 2002), indicated that
1 
 
 
 
g/ml is the optimal concentration allowing biochemical
detection of puromycin-labeled proteins with minimal distur-
bance of cellular functions (Fig. 1 C). DC maturation consid-
erably increased the quantity of high mol wt puromycin-
labeled proteins (50–250 kD) detected in the DALIS-enriched
fractions (Fig. 1 C, smear). These results suggest that the puro-
mycin-labeled proteins, as already described (Etlinger and
Goldberg, 1980), could be degraded like bona fide DRiPs in
 
Table I. 
 
Effect on DALIS maintenance of different drugs altering protein synthesis
Concentration Known effect on protein synthesis Effect on DALIS
 
Control
 
 
 
-Amanitin 10 
 
 
 
g/ml mRNA synthesis inhibition
T-2 toxin 10 
 
 
 
g/ml First peptidyl transfer (Met-AA
 
1
 
) 
inhibition
Anisomycin 10 
 
 
 
g/ml Peptidyl transfer inhibition
Cycloheximide 25 
 
 
 
M Ribosomal translocation inhibition
Emetine 25 
 
 
 
M Ribosomal translocation inhibition
Canavanin 15 mM Arginine analogue giving rise to 
newly synthesized abnormal proteins
Puromycin 5 
 
 
 
g/ml Incorporation to the growing end of 
the polypeptide chain and translation 
premature termination giving rise to 
incomplete proteins (DRiPs)
Drugs affecting either transcription or translation were added for 1 h to maturing DCs (8 h LPS) before DALIS observation by confocal microscopy. 
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Figure 1. Puromycin-containing proteins are 
targeted to DALIS during DC maturation. 
(A) Maturing DCs (8 h LPS) were treated with 0.1–5.0 
 g/ml of puromycin for 30 min before 1% Triton 
X-100 extraction and fixation. DCs were stained 
for puromycin (left) and ubiquitinated proteins 
(Ub-proteins, right), and were visualized by confocal 
microscopy. Puromycin is detected in DALIS 
(arrows). Note that the highest dose of puromycin 
(5  g/ml) induced de novo formation of aggregates. 
(B) Top: co-treatment with 100  M cycloheximide 
(CHX) abolishes puromycin incorporation in DALIS 
(arrow), which is solely due to newly synthesized 
puromycin-containing proteins. Middle: in immature 
DCs, no DALIS formation is observed, neither is 
accumulation of puromycin-containing proteins. 
Bottom: puro-proteins incorporated into DALIS 
resist sequential biochemical extraction with 1% 
Triton X-100, 100  g/ml Dnase I, and 2 M NaCl. 
(C) Immature (No LPS) or maturing DCs (8 h LPS) 
were treated with 0.1–5.0  g/ml puromycin for 30 
min. DCs were submitted to biochemical extraction, 
and puromycin-containing proteins present in the 
final insoluble pellet were analyzed by immunoblot. 
Bar, 10  m.
Figure 2. Puromycin-labeled proteins are rapidly 
incorporated in the central area of DALIS by a 
mechanism independent of microtubules or actin 
filaments. (A) Puromycin-labeled protein (green) 
incorporation into DALIS (red, arrows) is visualized as 
soon as 5 min after puromycin was added. (B) Maturing 
DCs were treated with 0.5  g/ml puromycin for 15 
min. After extraction with 1% Triton X-100, nucleus 
(N) and DALIS (arrows) were visualized by DIC or by 
immunofluorescence. Puro-protein (green) incorporation 
takes place right in the center of DALIS labeled by 
Ub-proteins (red), as illustrated by the yellow overlap 
in the combined xy, xz, and yz view. The inset displays 
a higher magnification view of a DALIS by DIC. 
(C) Disruption of microtubules with nocodazole before 
the puromycin pulse had no effect on puro-protein 
(green) incorporation in DALIS or on interaction 
between DALIS (red), as illustrated by the combined 
xy, xz, and yz view. (D) Disruption of actin network 
(stained by phalloidin in green, control on the left) 
with latrunculin B (Lat B) for 10 min before a 30-min 
puromycin pulse neither disrupted DALIS (Ub-proteins, 
red, center) nor prevented the incorporation of puro-
proteins (green, right). Bars, 10  m for all panels. 
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immature DCs, and indicate that part of these molecules are ef-
ficiently targeted to DALIS during DC maturation.
 
Puromycin-labeled proteins are rapidly incorporated in 
the central area of DALIS by a mechanism independent 
of microtubules or actin
 
We investigated the conditions of puromycin-tagged protein
incorporation into DALIS during the early phase of DC matu-
ration (8 h with LPS). This incorporation is extremely rapid;
puromycin-labeled proteins were detected in the central zone
of DALIS as soon as 5 min after adding the antibiotic to DCs
(Fig. 2 A). This observation confirms the efficiency of mis-
folded protein targeting to DALIS and the potential implica-
tion of ribosomes in speeding up this process (Lelouard et al.,
2002). Confocal Z-sectioning showed that puromycin-labeled
proteins are incorporated at the center of the structure, and
not simply by a more random aggregation in the periphery like
classical aggresomes (Fig. 2 B; Kopito, 2000). Therefore, DA-
LIS have a specific structural organization with a center ex-
tremely active in defective protein recruitment. Interestingly,
differential interference contrast (DIC) microscopy revealed
that DALIS are not fully homogenous spherical structures be-
cause contrasted areas can be detected either intruding in or
 
protruding from their center (Fig. 2 B, enlarged frame). As ex-
pected, disrupting microtubules with nocodazole, which strongly
impairs aggresome but not DALIS formation (Lelouard et al.,
2002), had no effect on puromycin-labeled protein incorpora-
tion or DALIS organization as shown by Z-sectioning (Fig. 2
C). Treatment with latrunculin B, which destroys actin net-
works, did not interfere with puromycin-labeled protein accu-
mulation in DALIS (Fig. 2 D). Therefore, these results indi-
cate that DALIS are more complex than randomly associated
macromolecular aggregates, and seem to possess architectural
features able to incorporate newly improperly synthesized pro-
teins actively and rapidly through their center.
 
Dynamics of DALIS and ubiquitin in live DCs
 
The rapid incorporation of ubiquitinated proteins in DALIS
leads us to investigate this process in live DCs. We took ad-
vantage of a fusion of GFP with ubiquitin in COOH-termi-
nal position (GFP-Ub), which was shown to behave as mono-
meric ubiquitin (Qian et al., 2002). In particular, GFP-Ub
can be incorporated in ubiquitin polymers able to promote
protein degradation. Therefore, GFP-Ub was expressed in live
DCs using a retroviral system and was monitored by immu-
nofluorescence microscopy (Fig. 3). GFP-Ub accumulation in
Figure 3. DALIS are motile and constantly 
incorporate ubiquitin. Using a retroviral infection 
system, bone marrow progenitors expressing GFP-
tagged ubiquitin (GFP-Ub) were differentiated in 
DCs. (A) In MHC class II positive (red) maturing 
DCs, GFP-Ub (green) is targeted to DALIS (arrows) 
labeled with FK2 antibody (blue) as shown by 
confocal microcopy. (B) Video microscopy 
performed over 2 h demonstrates that in DCs 
visualized by DIC, GFP-Ub labeled DALIS (green, 
arrow) are motile and can fuse together. Large 
aggregates (arrowhead) are in general less motile. 
Bar, 2  m. (C) FRAP was performed on DALIS. 
Representative images obtained before and after 
photobleaching are presented sequentially. 
The mean fluorescence intensity measurement 
(max   240) plotted against time (real data in red 
and correlation curve in blue) is shown on the 
right. 50% fluorescence was recovered in 2 min, 
and 90% after 18 min. 
Regulation of DRiPs degradation in DCs |
 
 Lelouard et al. 671
 
DALIS was obvious from the intense fluorescence emanating
from the polyubiquitinated aggregates in maturing DCs (Fig.
3 A). Video and time-lapse confocal microscopy performed
on LPS-activated DCs expressing GFP-Ub revealed that DA-
LIS are motile (
 
 
 
0.3–0.5 
 
 
 
m/min) and can interact together
(Fig. 3 B and Video 1, available at http://www.jcb.org/cgi/
content/full/jcb.200312073/DC1), suggesting that part of the
aggregation process is mediated by fusion/interaction events.
However, interactions were clearly preeminent in the smaller
aggregates (
 
 
 
0.5 
 
 
 
m), indicating that DALIS are heteroge-
neous and that size itself has an important impact on DALIS
behavior. The technique of FRAP was then used to monitor
the dynamics of ubiquitin in DALIS at 8 h of maturation
(Fig. 3 C and Video 1). 50% of the GFP-Ub fluorescence in-
tensity was already recovered in 2 min, and almost full recov-
ery was achieved 18 min after photobleaching. These observa-
tions emphasize the strong dynamics of ubiquitin and/or
ubiquitinated protein recruitment in DALIS. Clearly, the
FRAP experiments indicate that the fusion events observed by
videomicroscopy are not necessarily required by large DALIS
to acquire new ubiquitinated material. Furthermore, the rela-
tively rapid speed of fluorescence recovery compared with the
delay required for DALIS formation suggests that direct ubiq-
uitination of proteins in DALIS could contribute (at least par-
tially) to GFP-Ub incorporation in the aggregates.
 
Incorporation in DALIS delays protein degradation
 
Improperly translated protein incorporation into DALIS
could also be followed kinetically by implementing puromy-
cin pulse and chase experiments. To evaluate the clearing ef-
ficiency of the several washes performed before the chase, ra-
dioactive labeling was performed during either the 30-min
Figure 4. DRiPs are ubiquitinated and stored in DALIS. 
(A) maturing DCs (8 h LPS) were pulsed with 1  g/ml 
puromycin together with 
35S-labeled Pro-Mix (puro   
35S) for 30 min and chased for the indicated time. 
Alternatively, 
35S was added alone for 30 min at the 
indicated time during the puromycin chase (puro → 
35S). Puromycin clearance efficiency during the chase 
was monitored by autoradiography of 1% Triton X-100 
soluble material (left) and by autoradiography of 
puromycin-labeled protein immunoprecipitation 
material (right). (B) Maturing DCs were pulsed with 
1  g/ml puromycin and chased for the indicated time. 
Puromycin-labeled proteins were visualized by confocal 
microscopy after detergent extraction. Even after 16 h 
of chase, puromycin-labeled proteins are detected in 
DALIS (arrows). (C) The maximal fluorescence intensity 
of puromycin-labeled proteins visualized by confocal 
microscopy was established for a statistically relevant 
number of DALIS (15   n   20) and was plotted 
against time of puromycin chase. (D) Proteasome 
inhibition (1  M epoxomicin) effect on puromycin-
labeled (gray bars) and polyubiquitinated (black bars) 
proteins stored in DALIS was estimated by the same 
fluorescence intensity measurement method (*, P   
0.005). (E) In the same experiment as above, puromycin-
containing proteins were detected in DALIS-enriched 
fractions by immunoblot. The formation of high mol 
wt ladders, characteristic of polyubiquitination, could 
be observed with time, and this independently of 
proteasome inhibition (Epox). (F) After 16 h of chase, 
proteasome inhibition clearly prevented the loss of 
puromycin-labeled material from DALIS-enriched 
fraction, suggesting that DRiP degradation takes place 
at this late stage of maturation. 
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puromycin pulse or at different times after washing out the
drug (Fig. 4 A). The detection of high mol wt proteins (nor-
mally lost in presence of puromycin; Fig. 4 A, left) and
the extremely limited retrieval of immunoprecipitated [
 
35
 
S]
puromycin-tagged proteins when radioactivity was added
after removing the antibiotic indicated that little con-
taminating puromycin was left or recycled during the chase.
The residency time of improperly translated proteins in DA-
LIS could therefore be evaluated during the early phase of
DC maturation (8 h LPS) after a puromycin pulse of 30
min, followed by a chase of several hours. Puromycin-
labeled proteins were still detected in DALIS by confocal
microscopy after 16 h of chase, indicating that at least a frac-
tion of these proteins is relatively long lived and resists deg-
radation (Fig. 4 B), although a clear loss of fluorescent signal
was observed. To estimate the time of puromycin-labeled
protein residency in DALIS, the maximum intensity of
fluorescence was measured in several large aggregates
(
 
 
 
0.7 
 
 
 
m) and was correlated with the time of puromycin
chase (Fig. 4 C). The half-time of residency was estimated to
be 3.9 h, a period 23 times longer than the average half-life
of DRiPs as monitored in fibroblasts (10 min; Princiotta
et al., 2003). Interestingly, puromycin-tagged protein resi-
dency could be increased by the proteasome inhibitor ep-
oxomicin, whereas the level of polyubiquitin present in DA-
LIS remained relatively constant (Fig. 4 D). When the same
samples were analyzed by immunoblotting of DALIS-
enriched insoluble fractions, no loss of puromycin-labeled
material during the chase could be detected (Fig. 4 E). On
the contrary, over the 8-h time course a strong increase in high
mol wt ladders, likely to correspond to ubiquitinated mate-
rial (Schubert et al., 2000), could be observed. Moreover,
proteasome inhibition had no effect on the total quantity of
puromycin material recovered in the insoluble DALIS-
enriched fraction during the 8 h of chase (Fig. 4 E). This
suggests that the epoxomicin effect on the residency time in
DALIS of puromycin-tagged protein (Fig. 4 D) was due to a
relocalization or stabilization of these proteins in the aggre-
gates rather than an inhibition of their degradation. How-
ever, proteasome inhibition during a longer period of chase
(16 h) considerably increased the accumulation of all forms
of puromycin-tagged molecules (Fig. 4 F), indicating that
between 8 and 16 h of chase proteasomal degradation of
puromycin-tagged proteins finally occurred.
Together, these results suggest that in maturing DCs, the
major part of DRiPs can be polyubiquitinated and stabilized
for periods (at least 8 h and up to 16 h) considerably longer
than their described half-life (Princiotta et al., 2003). Inter-
estingly, ubiquitination became obviously detectable 4 h af-
ter the pulse, a time at which the immunofluorescence data
indicate 50% of the puromycin-labeled proteins have tran-
sited through large DALIS (0.7 
 
 
 
m 
 
 
 
 diameter 
 
 
 
 2.1 
 
 
 
m).
Therefore, DALIS may be susceptible to loose ubiquitinated
material, still detectable by biochemistry in the insoluble
fractions and protected from degradation for a long period.
This may in part explain why DALIS growth is somehow
limited to a maximum size. Therefore, DRiPs are probably
ubiquitinated in DALIS and stored until proteasome-medi-
ated degradation is initiated between 8 and 16 h later (16–
24 h of maturation).
 
The ubiquitin-conjugating enzyme system is present 
in DALIS
 
The conversion with time of puromycin-labeled proteins
into a ladder of high mol wt forms suggests that ubiquitina-
tion occurs in DALIS. Thus, we investigated whether the
ubiquitin-activating enzyme E1 was present in DALIS. The
detection by confocal microscopy of this enzyme in the ag-
gregates (Fig. 5 A) confirmed our hypothesis and indicated
that a ubiquitination-conjugating machinery is present in
DALIS. E1 was found enriched at the center of the DALIS,
confirming our previous finding on DALIS organization
(Fig. 2 B). Interestingly, E1 expression was strongly in-
creased during the first 8 h of maturation, but the enzyme
could not be detected by immunoblotting in the insoluble
DALIS-enriched fractions (Fig. 5 B), which indicates that at
least a part of the DALIS functional machinery is sensitive to
the biochemical extraction procedure.
In addition to the E1 ubiquitin-activating enzyme, we in-
vestigated by immunofluorescence the cellular localization
of the ubiquitin-conjugating enzyme E2
 
25K
 
, homologous to
the yeast E2s UBC4/UBC5, which catalyses multi-ubiquitin
Figure 5. Regulation and DALIS targeting of the ubiquitin-
conjugation enzyme system during DC maturation. (A) The E1 
ubiquitin-activating enzyme (left) is present (arrow) in the central 
area of DALIS (Ub-proteins, right). (B) E1 expression strongly increased 
during the first 8 h of DC maturation without any change in its 
solubility, as monitored by immunoblot on soluble (top) and DALIS-
enriched (bottom) fraction. (C) The ubiquitin-conjugating enzyme 
E225K (left) is present (arrow) in DALIS (Ub-proteins, right). (D) E225K 
expression increased during the first 8 h of DC maturation without 
any change in its solubility, as monitored by immunoblot on soluble 
(top) and DALIS-enriched (bottom) fraction. (E) The E3 ubiquitin 
ligase CHIP (left) is present (arrow) in the central area of some 
DALIS (Ub-proteins, right) and absent from others (arrowheads). 
(F) During DC maturation, expression of CHIP (as detected by 
immunoblot) increases in DALIS-enriched fraction (bottom), but not 
in Triton X-100 soluble fraction (top). Bars, 10  m for all panels. 
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chain synthesis and mediates the selective degradation of
short-lived and abnormal proteins (Chen and Pickart, 1990;
Seufert and Jentsch, 1990). Like E1, E2
 
25K
 
 was present in
DALIS (Fig. 5 C), and its expression monitored by immu-
noblotting was increased during the first 8 h of maturation,
but could not be detected in the insoluble DALIS-enriched
fractions (Fig. 5 D).
Finally, in order to confirm that a complete ubiquitina-
tion machinery is present at the center of DALIS, we started
to evaluate the cellular distribution of several E3 ubiqui-
tin  ligases. The E3 ubiquitin ligase, COOH terminus of
Hsp70-interacting protein (CHIP), is a pivotal enzyme able
to influence the refolding or the degradation of proteins
both by interacting with heat shock molecules and mediat-
ing ubiquitination of misfolded substrates (Jiang et al.,
2001; Meacham et al., 2001; Murata et al., 2001; Cyr et al.,
2002). Therefore, CHIP was an interesting candidate E3
ubiquitin ligase to be tested in our system. CHIP was de-
tected in DALIS by confocal microscopy (Fig. 5 D). Impor-
tantly, CHIP was not detected in all DALIS, suggesting that
these structures might not all be equivalent, even in the same
cells. As expected, CHIP was also enriched at the center of
the DALIS, confirming the contribution of this zone in the
active recruitment and the ubiquitination of defective pro-
tein. Conversely to E1 and E2
 
25K
 
, CHIP was progressively
enriched in insoluble DALIS fractions, whereas its expres-
sion in the soluble fraction remained constant (Fig. 5 E).
Together, these results confirm the role of the central zone
of DALIS in the ubiquitination of DRiPs, and indicate that
the complete ubiquitin-conjugating enzyme system is regu-
lated during DC maturation.
 
Discussion
 
DRiPs are considered as one of the most important sources
of antigenic peptides presented by MHC class I in DCs and
other cells (Reits et al., 2000; Schubert et al., 2000; Khan et
al., 2001; Yewdell and Bennink, 2001; Princiotta et al.,
2003; Yewdell et al., 2003). Using puromycin-labeled pro-
teins as a model for DRiPs, we have unraveled their fate,
which is likely to influence MHC class I presentation during
DC maturation.
First, after their synthesis, DRiPs are rapidly targeted to
the center of DALIS in maturing DCs. This rapid entry at a
specific site implies that DALIS have a complex structural
organization, probably involving specific scaffold proteins
and enzymes likely to participate actively in improperly
translated protein recruitment. Together with the fact that
ribosomal proteins are found in close vicinity with DALIS
(Lelouard et al., 2002), this observation may also indicate
that the translation apparatus and its associated chaperone
machinery could be directly involved in the process of selec-
tion and inclusion of DRiPs into DALIS.
Second, DRiP ubiquitination occurs at this central loca-
tion. This was primarily suggested by the rapid replacement
of the GFP-Ub in DALIS monitored by FRAP, and by the
appearance of high mol wt puromycin-labeled proteins
forming ladders in the DALIS-enriched fractions after chas-
ing the antibiotic for relatively short times. The detection in
DALIS of the ubiquitin-activating enzyme E1, the ubiq-
uitin-conjugating enzyme E2
 
25K
 
, and the E3 ubiquitin ligase
CHIP, required respectively for all the steps of misfolded
protein ubiquitination, confirms that DALIS can serve as
ubiquitination areas for DRiPs. Their enrichment in the
central area of DALIS also suggests that aberrant protein en-
try and ubiquitination at specific sites are well coordinated.
Moreover, although CHIP, which is likely to bind the ubiq-
uitination substrates, remains tightly associated with DALIS
under stringent conditions, the E1 and E2
 
25K
 
 enzymes are
efficiently removed by the same treatment, indicating that
soluble components are also part of the DALIS machinery.
This situation clearly distinguishes DALIS from classical
protein aggregates generally defined as simple storage units
of insoluble molecules (Kopito, 2000). Importantly, the
identified E1, E2, and E3 enzymes are all modulated during
DC maturation; E1 and E2 being up-regulated while the in-
solubility of CHIP is increased, thus inferring that these en-
zymes have important function during DC maturation. The
fact that ubiquitination occurs in DALIS also indicates that
it is not a prerequisite for DRiPs targeting to DALIS, and
may explain why other ubiquitinated proteasome substrates
such as IkB-
 
 
 
 are not incorporated in the aggregates (Lel-
ouard et al., 2002).
Third, DRiP accumulation in DALIS considerably ex-
tends the half-life of these abnormal proteins by preventing
proteasome-mediated degradation. The efficiency in delay-
ing DRiP degradation is quite high, as judged by the inabil-
ity of proteasome inhibition to increase the quantity of
puromycin-labeled proteins detected by immunoblot in the
first 8 h after puromycin incorporation (16 h after the acti-
vation of DCs). The estimated half-time of residency of
puromycin-labeled proteins (4 h after the puromycin pulse)
and the stability of polyubiquitin levels in DALIS during the
first 8 h also implies the existence of an equilibrium between
the number of DRiPs entering and exiting DALIS after
ubiquitination. Moreover, it suggests that at this stage of
DC maturation (8–16 h of maturation), part of the ubiqui-
tinated DRiPs can be stored and protected from degradation,
even after exiting large DALIS structures (0.7 
 
 
 
m 
 
 
 
 diame-
ter 
 
 
 
 2.1 
 
 
 
m). In this condition, the stronger retention in
DALIS of puromycin-labeled proteins observed after epoxo-
micin treatment could be due to an indirect effect of protea-
some inhibition on many ubiquitin-based processes, rather
than purely a block in the degradation of DRiPs stored in
the aggregates. 
Fourth, between 8 and 16 h of chase (16–24 h of DC
maturation), DRiP degradation by the proteasome is clearly
resumed.
DRiP fate during DC maturation has to be further inte-
grated with the process of DALIS formation, maintenance,
and disappearance. Videomicroscopy imaging using the
GFP-Ub chimera indicates that DALIS are dynamic and can
interact with each other (although in a heterogeneous man-
ner). Therefore, DALIS formation could occur in several
steps, first involving the assembly of “microaggregates,” fol-
lowed by the fusion of the smaller and apparently more dy-
namic aggregates, and ending with the stabilization of the
larger structures storing at that point the bulk of the DRiP
production. The integrity of the larger structures could be
dependent on the activity of the translation machinery, as 
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demonstrated by the exquisite sensitivity of the aggregates to
protein synthesis inhibitors. The translation machinery, in
addition to producing DRiPs, could also provide some
structural elements important to maintain the cohesion of
large DALIS.
The efficient storage of large quantities of DRiPs during
DC maturation is a puzzling phenomenon. The importance
of DRiPs as an antigen source is such that a block/delay in
their processing is likely to influence the MHC class I pre-
sentation in maturing DCs. The immunological conse-
quences of this regulation remain to be fully evaluated. It has
been recently proposed that DRiP processing and presenta-
tion is likely to be important for viral antigen presentation
(Yewdell et al., 2003); the storage of important viral deter-
minants by DCs would therefore appear to be a counterpro-
ductive defense strategy. However, new evidences suggest
that viral antigen presentation by DCs is occurring mainly
via cross-presentation (Lizée et al., 2003). This phenomenon
is independent of direct viral protein synthesis by the DCs,
and could be in fact favored by DALIS formation. Our work
suggests that DALIS are organized structures performing co-
ordinated biochemical functions, and that large protein ag-
gregates might not be as amorphous as previously believed.
Furthermore, the time frame of our observations implies
that many important processes occurring in the first hours of
DC activation have probably been overlooked.
 
Materials and methods
 
All chemicals were purchased from Sigma-Aldrich except epoxomicin,
which was purchased from Affiniti Research Products.
 
Cell culture
 
7–8-wk-old male C57BL/6 mice were purchased from Charles River Labo-
ratories. Bone marrow-derived DCs were cultured as described previously
(Lelouard et al., 2002). mAbs TIB120, GK1.5, TIB 211, and B220 were ob-
tained as hybridomas from the American Type Culture Collection (Gai-
thersberg, MD). Recombinant murine GM-CSF was produced as culture
supernatant from J558L cells transfected with the murine GM-CSF cDNA
(a gift of Dr. D. Gray, University of Edinburgh, Edinburgh, UK). Immature
cell clusters were purified by unit gravity sedimentation on 6-ml 50% FCS
columns. Maturation was induced using 100 ng/ml LPS.
 
Antibodies and immunocytochemistry
 
DCs were harvested and coated on 1% alcian blue–treated coverslips for 5
min at 37
 
 
 
C, permeabilized (or not) with 1% Triton X-100 in PBS for 5 min
at 4
 
 
 
C, and fixed with 3% PFA in PBS for 10 min at RT. Rabbit pAb against
puromycin was the gift of Peter Walter (University of California, San Fran-
cisco, CA). Rabbit pAb against CHIP was the gift of Cam Peterson (Univer-
sity of North Carolina, Chapel Hill, NC). mAb FK1, FK2, and rabbit pAb
against E1 and E2
 
25K
 
 were obtained from Affiniti Research Products. mAb
against E1 was from Sigma-Aldrich. All Alexa
 
®
 
 secondary antibodies were
from Molecular Probes, Inc. Immunofluorescence and confocal micros-
copy (using microscope model LSM 510; Carl Zeiss MicroImaging, Inc.)
were performed as described previously (Lelouard et al., 2002).
 
Pharmacological treatments
 
DCs were incubated, unless stated otherwise, with 0.5 or 1 
 
 
 
g/ml puromy-
cin for 30 min. 1 
 
 
 
M epoxomicin was added for indicated times. 100 
 
 
 
M
cycloheximide, 5 
 
 
 
M latrunculin B, or 10 
 
 
 
g/ml nocodazole were added
10 min before puromycin pulse.
 
Live imaging and FRAP
 
GFP-ubiquitin cDNA was the gift of J. Yewdell (National Institutes of
Health, Bethesda, MD), and the LZRS retroviral vector was from G. Nolan
(Stanford Universitty, Stanford, CA). Bone marrow progenitors were in-
fected with LZRS recombinant retroviruses engineered to express GFP-Ub
 
as described previously (Chow et al., 2002). After differentiation in DCs,
GFP-expressing cells incubated for 8 h with LPS were used for live imag-
ing. Videomicroscopy at 37
 
 
 
C in 5% CO
 
2
 
 was performed with an inverted
microscope (Leica) equipped with a PentaMAX™ CCD camera (Princeton
Instruments). Images were collected every 2 min for 3 h and processed
with MetaMorph
 
®
 
 version 5 (Universal Imaging Corp.). FRAP was per-
formed on a confocal microscope (model LSM 510; Carl Zeiss MicroImag-
ing, Inc.) using an argon laser 488-nm ray with a power of 12.5 mW ap-
plied for 5 s to a selected spot containing DALIS (average of 1-
 
 
 
M radius).
Fluorescence recovery was observed at 37
 
 
 
C by collecting 15 consecutive
0.5-
 
 
 
M slices every 2 min with a laser power of 1.25 mW. Images were
analyzed and quantified with LSM Image Examiner software (Carl Zeiss
MicroImaging, Inc.), MetaFluor version 5.0 (Universal Imaging Corp.), and
Igor (Wavemetrics). No obvious loss of fluorescence was detected in con-
trol areas after FRAP on DALIS.
 
Selective enrichment of DALIS
 
DCs were submitted to a 30-min extraction with 1% Triton X-100 in 20
mM Tris, pH 7.4, 1.5 mM MgCl
 
2
 
, and 10 mM NaCl at 4
 
 
 
C before a 30-min
DNase (100 
 
 
 
g/ml) treatment at 37
 
 
 
C in the same buffer. Nuclear material
extraction was then performed for 30 min at 4
 
 
 
C with 2 M NaCl in 20 mM
Tris, pH 7.4, and 1.5 mM MgCl
 
2
 
. Remaining material was PBS washed and
submitted to immunocytochemical and biochemical analysis.
 
Radiolabeling, immunoprecipitation, and immunoblots
 
10
 
6
 
 DCs were pulse labeled with 1 
 
 
 
g/ml puromycin, and in some cases
with 10 mCi/ml of [
 
35
 
S]methionine Pro-Mix (APB) for 30 min, washed, and
chased for various time at 37
 
 
 
C in RPMI 1640/5% FCS as described previ-
ously (Lelouard et al., 2002). Triton X-100 soluble or DALIS-enriched frac-
tions were analyzed before or after immunoprecipitation with anti-puromy-
cin antibody. Material separation onto 2–10% gradient SDS-PAGE gels and
immunoblots was performed as described previously (Lelouard et al., 2002)
and was revealed by chemiluminescent detection (Pierce Chemical Co.).
 
Online supplemental material
 
Time-lapse confocal microscopy (five slices of 0.5 
 
 
 
m every 2 min for 1 h)
followed by a FRAP experiment performed on GFP-Ub expressing DCs af-
ter 8 h in LPS. Pictures were superimposed and assembled sequentially in
time. Small DALIS fusion with larger aggregates can be observed as well as
rapid FRAP. Online supplemental material available at http://www.jcb.org/
cgi/content/full/jcb.200312073/DC1.
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